INTERNATIONAL PERSONAL FINANCE
Numis recommends that investors buy shares in the loans company and has increased the target price from 644p to 675p. The broker has hiked its earnings per share forecasts to reflect IPF’s dominance of the home credit market and a £50m share buyback.
UBS sticks to a “buy” rating for the pharmaceutical company, raising the target price from 4,600p to 4,825p. The broker thinks AstraZeneca’s recent progress in advancing its drug pipeline will raise its value as Pfizer continues to make merger advances.